Top

BMC Cancer

Published in:

Open Access 01-12-2024 | Breast Cancer | Research

Upregulation of CENPM promotes breast carcinogenesis by altering immune infiltration

Authors: Yanchu Tong, Tongzhou Zhou, Xiaokun Wang, Shun Deng, Lu Qin

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

The involvement of centromere protein M (CENPM) in various types of cancer has been established, however, its impact on breast cancer and immune infiltration remains unknown.

Methods

We examined the expression of CENPM in different cancer types by utilizing the Cancer Genome Atlas (TCGA) and Genotype Tissue Expression Pan-Cancer (GEO) databases. Using data from the TCGA, we examined the correlation between the expression of CENPM, the prognosis, and the clinicopathological features of individuals diagnosed with breast cancer. We conducted an enrichment analysis of CENPM using the clusterProfiler R software tool, utilizing data obtained from breast cancer patients and specimens at our institution. In addition to examining the correlation between CENPM expression and genes associated with immune checkpoints, the TIDE algorithm was employed to explore the potential of CENPM as a biomarker for immunotherapy in breast cancer. The impact of CENPM on the growth of breast cancer cells was evaluated through the utilization of the CCK8 test and the colony formation assay. The effect of CENPM on the migration of breast cancer cells was assessed using scratch and transwell assays.

Results

Research findings indicate that elevated levels of CENPM are linked to patient outcomes in breast cancer and various clinicopathological features. Furthermore, elevated levels of CENPM expression correlated with decreased levels of CD8 + T cells and mast cells, increased levels of Tregs and Th2, and reduced levels of CD8 + T cells. Additionally, the coexpression of CENPM with the majority of genes related to immune checkpoints indicates its potential to forecast the effectiveness of treatment in breast cancer. Suppression of CENPM hampers the growth and movement of breast tumor cells.

Conclusions

In summary, our study findings indicate that CENPM may serve as a cancer-causing gene in breast cancer and also as a biomarker for predicting the efficacy of immunotherapy.

The oncogene CENPM is associated with breast cancer and is involved in cell proliferation and immune infiltration.

Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708. [published Online First: 2022/01/13].

Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet. 2021;397(10286):1750–69. https://doi.org/10.1016/S0140-6736(20)32381-3. [published Online First: 2021/04/05].

Tsang JYS, Tse GM. Molecular classification of breast Cancer. Adv Anat Pathol. 2020;27(1):27–35. https://doi.org/10.1097/PAP.0000000000000232. [published Online First: 2019/05/03].

Barzaman K, Karami J, Zarei Z, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535. https://doi.org/10.1016/j.intimp.2020.106535. [published Online First: 2020/05/04].

Saatci O, Huynh-Dam KT, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med (Berl). 2021;99(12):1691–710. https://doi.org/10.1007/s00109-021-02136-5. [published Online First: 2021/10/09].

Zhang J, Xia Y, Zhou X, et al. Current landscape of personalized clinical treatments for triple-negative breast cancer. Front Pharmacol. 2022;13:977660. https://doi.org/10.3389/fphar.2022.977660. [published Online First: 2022/10/04].

Hinohara K, Polyak K. Intratumoral Heterogeneity: more Than just mutations. Trends Cell Biol. 2019;29(7):569–79. https://doi.org/10.1016/j.tcb.2019.03.003. [published Online First: 2019/04/17].

van den Ende NS, Nguyen AH, Jager A, et al. Triple-negative breast Cancer and predictive markers of response to Neoadjuvant Chemotherapy: a systematic review. Int J Mol Sci. 2023;24(3):69. https://doi.org/10.3390/ijms24032969. [published Online First: 2023/02/12].

Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32. https://doi.org/10.1002/cncr.22381. [published Online First: 2006/12/06].

10.

Yue Y, Astvatsaturyan K, Cui X, et al. Stratification of prognosis of Triple-negative breast Cancer patients using combinatorial biomarkers. PLoS One. 2016;11(3):e0149661. https://doi.org/10.1371/journal.pone.0149661. [published Online First: 2016/03/02].

11.

Diana A, Carlino F, Franzese E, et al. Early triple negative breast Cancer: Conventional Treatment and emerging therapeutic landscapes. Cancers (Basel). 2020;12(4):819. https://doi.org/10.3390/cancers12040819. [published Online First: 2020/04/03].

12.

Shen M, Pan H, Chen Y, et al. A review of current progress in triple-negative breast cancer therapy. Open Med (Wars). 2020;15(1):1143–9. https://doi.org/10.1515/med-2020-0138. [published Online First: 2020/12/19].

13.

So JY, Ohm J, Lipkowitz S, et al. Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options. Pharmacol Ther. 2022;237:53. https://doi.org/10.1016/j.pharmthera.2022.108253. [published Online First: 2022/07/26].

14.

Zheng C, Zhang T, Li D, et al. Upregulation of CENPM facilitates tumor metastasis via the mTOR/p70S6K signaling pathway in pancreatic cancer. Oncol Rep. 2020;44(3):1003–12. https://doi.org/10.3892/or.2020.7673. [published Online First: 2020/07/25].

15.

Xiao Y, Najeeb RM, Ma D, et al. Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms. J Exp Clin Cancer Res. 2019;38(1):458. https://doi.org/10.1186/s13046-019-1444-0. [published Online First: 2019/11/11].

16.

Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8. https://doi.org/10.1038/s41591-018-0136-1. [published Online First: 2018/08/22].

17.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. https://doi.org/10.1093/nar/28.1.27. [published Online First: 1999/12/11].

18.

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51. https://doi.org/10.1002/pro.3715. [published Online First: 2019/08/24].

19.

Kanehisa M, Furumichi M, Sato Y, et al. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92. https://doi.org/10.1093/nar/gkac963. [published Online First: 2022/10/28].

20.

Katsura C, Ogunmwonyi I, Kankam HK, et al. Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond). 2022;83(2):1–7. https://doi.org/10.12968/hmed.2021.0459. [published Online First: 2022/03/05].

21.

Lorenzo R, Meani F, Longhitano C, et al. The optimal timing between neoadjuvant therapy and surgery of breast cancer: a brief systematic review of the literature. Crit Rev Oncol Hematol. 2023;183: 103921. https://doi.org/10.1016/j.critrevonc.2023.103921. [published Online First: 2023/02/07].

22.

Scott LC, Mobley LR, Kuo TM, et al. Update on triple-negative breast cancer disparities for the United States: a population-based study from the United States Cancer statistics database, 2010 through 2014. Cancer. 2019;125(19):3412–7. https://doi.org/10.1002/cncr.32207. [published Online First: 2019/07/10].

23.

Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–21. https://doi.org/10.1002/jcp.27782. [published Online First: 2018/12/07].

24.

van Dalen FJ, van Stevendaal M, Fennemann FL, et al. Molecular Repolarisation of Tumour-Associated macrophages. Molecules. 2018;24:1. https://doi.org/10.3390/molecules24010009. [published Online First: 2018/12/24].

25.

Cozar B, Greppi M, Carpentier S, et al. Tumor-infiltrating natural killer cells. Cancer Discov. 2021;11(1):34–44. https://doi.org/10.1158/2159-8290.CD-20-0655. [published Online First: 2020/12/06].

26.

Pitt JM, Marabelle A, Eggermont A, et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–92. https://doi.org/10.1093/annonc/mdw168. [published Online First: 2016/04/14].

27.

Mao Y, Qu Q, Zhang Y, et al. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One. 2014;9(12):e115103. https://doi.org/10.1371/journal.pone.0115103. [published Online First: 2014/12/17].

28.

Raskov H, Orhan A, Christensen JP, et al. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124(2):359–67. https://doi.org/10.1038/s41416-020-01048-4. [published Online First: 2020/09/16].

29.

Li C, Jiang P, Wei S, et al. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19(1):116. https://doi.org/10.1186/s12943-020-01234-1. [published Online First: 2020/07/19].

30.

Mehta AK, Kadel S, Townsend MG, et al. Macrophage Biology and mechanisms of Immune suppression in breast Cancer. Front Immunol. 2021;12: 643771. https://doi.org/10.3389/fimmu.2021.643771. [published Online First: 2021/05/11].

31.

Cassetta L, Fragkogianni S, Sims AH, et al. Human Tumor-Associated Macrophage and Monocyte Transcriptional landscapes Reveal Cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 2019;35(4):588-602e10. https://doi.org/10.1016/j.ccell.2019.02.009. [published Online First: 2019/04/02].

32.

Wang J, Li D, Cang H, et al. Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019;8(10):4709–21. https://doi.org/10.1002/cam4.2327. [published Online First: 2019/06/22].

33.

Choi J, Gyamfi J, Jang H, et al. The role of tumor-associated macrophage in breast cancer biology. Histol Histopathol. 2018;33(2):133–45. https://doi.org/10.14670/HH-11-916. [published Online First: 2017/07/07].

Title: Upregulation of CENPM promotes breast carcinogenesis by altering immune infiltration
Authors: Yanchu Tong
Tongzhou Zhou
Xiaokun Wang
Shun Deng
Lu Qin
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11808-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

25-hydroxycholesterol promotes proliferation and metastasis of lung adenocarcinoma cells by regulating ERβ/TNFRSF17 axis

Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma

Correction: Clinical features and imaging examination assessment of cervical lymph nodes for thyroid carcinoma

p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer

A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)

Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China

Keynote webinar | Spotlight on antibody–drug conjugates in cancer